News Quantified

AKTX – akari therapeutics plc - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

Akari Therapeutics (AKTX) was downgraded by Maxim Group from "buy" to "hold".

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Akari Therapeutics (AKTX) had its price target raised by HC Wainwright from $1.60 to $27.00. They now have a "buy" rating on the stock.

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Top News Gainers

8/14 Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) 30.9%

1/10 Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study 25.6%

8/29 Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress 12.2%

2/20 Akari Therapeutics, Plc Announces Private Placement 8.2%

11/27 Form 6-K Akari Therapeutics Plc For: Nov 27 7.9%

3/26 Form F-3 Akari Therapeutics Plc 5.7%

6/28 Form 6-K Akari Therapeutics Plc For: Jun 28 5.4%

12/5 Regeneron's pozelimab shows positive effect in PNH study [Seeking Alpha] 5.3%

12/2 Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting 4.9%

9/13 Akari Therapeutics PLC (NASDAQ: AKTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 4.8%

Top News Decliners

5/1 Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients -24.4%

3/13 Akari Therapeutics PLC (NASDAQ: AKTX) had its price target lowered by analysts at B. Riley from $7.00 to $5.00. They now have a "buy" rating on the stock. -15.4%

4/2 Akari Therapeutics PLC (NASDAQ: AKTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock. -15.2%

9/13 Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid -12.8%

10/10 Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress -12.0%

8/30 Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co? -11.1%

3/11 Form D Akari Therapeutics Plc -10.5%

8/9 Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease -9.8%

12/23 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND -8.9%

9/3 Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day